Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer Stage IV
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04953962
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States
🇺🇸Ochsner Clinic Foundation, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT03113188
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 195
- Registration Number
- NCT00942825
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸Mary Crowley Cancer Research Centers, Dallas, Texas, United States
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
- Conditions
- Malignant Pleural MesotheliomaSolid Tumors
- Interventions
- Drug: pemetrexed, cisplatin and CBP501Drug: pemetrexed, cisplatin and CBP501, dose finding
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT00700336
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
- Conditions
- CancerSolid Tumors
- Interventions
- Drug: CBP501 and Cisplatin
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- CanBas Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT00551512
- Locations
- 🇺🇸
Scottsdale Clinical Research Institute, Scottsdale, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Nevada Cancer Institute, Las Vegas, Nevada, United States